depistage
PreclinicalBiologic
depistage is one of 22 biologic programs targeting Prospective. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Prospective
#DrugCompanyPhaseTrials
1Tnkase
RocheApproved
Zeposia
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Venclexta
AbbViePhase 3
Nexavar
BayerPhase 3
Cytosar
TevaPhase 3
Xiidra
BBausch Health Americas, Inc.
Approved
Mulpleta
IItalian Network for Tumor Biotherapy Foundation
Approved
Beyfortus
BeiGenePhase 2
Imbruvica
PPharmacyclics LLC.
Phase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for depistage. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Limoges